Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia.

@article{Musto2008SalvageTW,
  title={Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia.},
  author={Pellegrino Musto and Giuseppe Pietrantuono and Roberto Guariglia and Oreste Villani and Maria Carmen Martorelli and Fiorella D'Auria and Antonia Zonno and Rosa Lerose},
  journal={Leukemia research},
  year={2008},
  volume={32 10},
  pages={1637-8}
}
2] Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood 2005;106(August 15 (4)):1207–9 [Epub April 28, 2005]. 3] Ceesay MM, Lea NC, Ingram W, et al. The JAK2 V617F mutation is rare in RARS but common in RARS-T… CONTINUE READING